Prev: Molecular Testing for Cancer Prognosis and Outcome
Next: Abiraterone, New treatment?
From: kh on 23 Jul 2008 08:42
On Jul 23, 7:58 am, Mik...(a)anon.com wrote:

> J, it's right the clinical research said Docetaxel had to have been
> used and failed on trialists.  That's the fatal, uncurable, type the
> research has focussed on.

Even at Stage 3, abiraterone is "experimental". Of course, the trial
is limited to "labrats" (like me), everything else has failed them,
they have nothing to lose. I'm sure they're all hoping that it works
for them but these are guys who are in pain, with mets, having failed
Lupron, Taxotere, and are looking at a bleak future.

Taxotere plus CNTO(328) is working well for me, so I'm not a candidate
for abiraterone, not yet.

> So it should surely block the cancer when it is present, at whatever
> stage.

I'm guessing that this one gets fast-tracked, they stop the trials,
and open it up before 2 years. They won't have the long-term stats
in but who cares.

I agree with Mike, they're doing advanced cases because the advanced
have nothing to lose. Give us some hope and we'll sign up for the
"human trials".

If abiraterone works anything like the reports, it will replace Lupron
in 2 or 3 years and probably make Watchful Waiting, with intermittent
abiraterone, the treatment of choice in 5 years. This is way
optimistic but why go for radiation or surgery?

Imagine a future where this disease is controlled by a couple
pills. It could happen.

-kh
From: tarhoosier on 23 Jul 2008 09:31
On Jul 23, 8:42 am, kh <tch...(a)yahoo.com> wrote:
> On Jul 23, 7:58 am, Mik...(a)anon.com wrote:
>
> > J, it's right the clinical research said Docetaxel had to have been
> > used and failed on trialists. That's the fatal, uncurable, type the
> > research has focussed on.
>
> Even at Stage 3, abiraterone is "experimental". Of course, the trial
> is limited to "labrats" (like me), everything else has failed them,
> they have nothing to lose. I'm sure they're all hoping that it works
> for them but these are guys who are in pain, with mets, having failed
> Lupron, Taxotere, and are looking at a bleak future.
>
> Taxotere plus CNTO(328) is working well for me, so I'm not a candidate
> for abiraterone, not yet.
>
> > So it should surely block the cancer when it is present, at whatever
> > stage.
>
> I'm guessing that this one gets fast-tracked, they stop the trials,
> and open it up before 2 years. They won't have the long-term stats
> in but who cares.
>
> I agree with Mike, they're doing advanced cases because the advanced
> have nothing to lose. Give us some hope and we'll sign up for the
> "human trials".
>
> If abiraterone works anything like the reports, it will replace Lupron
> in 2 or 3 years and probably make Watchful Waiting, with intermittent
> abiraterone, the treatment of choice in 5 years. This is way
> optimistic but why go for radiation or surgery?
>
> Imagine a future where this disease is controlled by a couple
> pills. It could happen.
>
> -kh

According to Dr. Lam in the U. S., director of one of the sites for
the Phase III trial, there are plans for another Phase III open before
the end of this year for men who are docetaxel naive. I believe that
targeting tax failures first puts the medicine into those most in need
and also means that the opposing placebo arm of the trial is unlikely
to compete against AA. There is currently no approved therapy for tax
failed PCa patients, thus the bar is "low" for AA in this setting. And
results for tax failures will be in a short time line, unlike for
others who have an overall survival measured in years
From: Steve Jordan on 23 Jul 2008 16:23
(snip popular press article)

This was a Phase One trial, the purpose of which is to determine safe
dosage levels, among other things.

It appears nevertheless to be cause for hope, but we've all seen that
before.

Fingers crossed but not hyperventilating. Yet. There is a long way to go.

Here's the hard science:

Attard G, et al., "Phase I Clinical Trial of a Selective Inhibitor of
CYP17, Abiraterone Acetate, Confirms That Castration-Resistant
Prostate Cancer Commonly Remains Hormone Driven." J Clin Oncol. 2008
Jul 21.

Conclusion, in pertinent part: "CYP17 blockade by abiraterone acetate
is safe and has significant antitumor activity in CRPC*.

*Castration Resistant Prostate Cancer

See www.pubmed.gov which is a service of the US National Library of
Medicine.

Search on PMID: 18645193

Regards,

Steve J

From: J on 23 Jul 2008 18:05
kh wrote:

> On Jul 23, 7:58 am, Mik...(a)anon.com wrote:
>
>
> Taxotere plus CNTO(328) is working well for me, so I'm not a candidate
> for abiraterone, not yet.
>
> > So it should surely block the cancer when it is present, at whatever
> > stage.
>
> I'm guessing that this one gets fast-tracked, they stop the trials,
> and open it up before 2 years. They won't have the long-term stats
> in but who cares.
>
> I agree with Mike, they're doing advanced cases because the advanced
> have nothing to lose. Give us some hope and we'll sign up for the
> "human trials".
>
> If abiraterone works anything like the reports, it will replace Lupron
> in 2 or 3 years and probably make Watchful Waiting, with intermittent
> abiraterone, the treatment of choice in 5 years.

Or if it's not better than what's currently available, they'll have used
up the medicine they've produced for the clinical trials and that'll be
the end of it.
J

First  |  Prev  | 
Pages: 1 2 3
Prev: Molecular Testing for Cancer Prognosis and Outcome
Next: Abiraterone, New treatment?